CERo Therapeutics Q2 2025 Earnings Report

CERo Therapeutics EPS Results

• Actual EPS: -$61.71
• Consensus EPS: -$70.23
• Beat/Miss: Beat by +$8.52
• One Year Ago EPS: N/A

CERo Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CERo Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/22/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

CERo Therapeutics (NASDAQ:CERO) is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancer. The company’s technology is designed to expand the capabilities of conventional T cells by combining targeted tumor-cell recognition and killing with phagocytic activity, potentially enabling immune cells to engulf and eliminate malignant cells.

CERo’s lead product candidate is CER-1236, an engineered T-cell therapy directed at CD123, a cell-surface protein expressed on several hematologic malignancies, including acute myeloid leukemia. The company has been advancing CER-1236 toward clinical development and is evaluating its potential in patients with relapsed or refractory blood cancers. Its broader research programs are focused on applying the company’s engineered-cell platform to additional oncology targets.

The company was established to develop next-generation cellular immunotherapies and became publicly traded through a business combination with Phoenix Biotech Acquisition Corp. in 2024. CERo Therapeutics is focused primarily on research, development and clinical testing rather than commercial product sales, and its therapies are not yet broadly available.